Investment highlights 2017-04-28T04:33:12+00:00

Investment Highlights

prescient therapeutics investment highlights
  • 2 targeted therapies with impeccable scientific pedigree

  • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials

  • One of deepest clinical pipelines on the ASX
    – Targeting important areas of unmet clinical need

  • Funded through to value-accretive catalysts, with a fantastic share register

  • Phase 1b/2 AML trial is being led by renowned leukemia expert, Dr Jeff Lancet
    – Dr Lancet was also the Principal Investigator on Celator Pharmaceuticals’ ground-breaking VYXEOS trial in AML

  • Great scientific and clinical team with a proven record of success

  • Multiple catalysts this year